Latest Conference Articles

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma

Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.

Belantamab Mafodotin Plus BPd Elicits PFS Benefit in R/R Myeloma

Belantamab mafodotin plus BPd improved PFS vs PVd in relapsed/refractory multiple myeloma.

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer

Inavolisib plus palbociclib and fulvestrant reduced the risk of progression or death in HR+/HER2– PIK3CA-mutated advanced or metastatic breast cancer.

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer

Anthracycline/taxane/cyclophosphamide was linked to improved RFS in MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

Compared with standard-of-care chemotherapy, adagrasib significantly improved PFS and tumor responses in KRASG12C-mutated locally advanced or metastatic NSCLC.

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.

Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC

Subcutaneous amivantamab was displayed noninferiority in terms of ORR vs intravenous administration in EGFR-mutated non–small cell lung cancer.

Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma

Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.

Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC

Amivantamab plus lazertinib improved progression-free survival vs osimertinib as frontline therapy in patients with high-risk, EGFR-mutant advanced NSCLC.

BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.